248. グルコーストランスポーター1欠損症 ［臨床試験数：18，薬物数：7（DrugBank：1），標的遺伝子数：0，標的パスウェイ数：0］
Searched query = "Glucose transporter type 1 deficiency", "GLUT1 deficiency"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03301532 | June 5, 2018 | 11 November 2019 | Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1D | Compatibility of Triheptanoin (C7) With the Ketogenic Diet in Patients Diagnosed With Glucose Transporter Type 1 Deficiency | GLUT1DS1 | Drug: Triheptanoin | University of Texas Southwestern Medical Center | National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting | 30 Months | 35 Years | All | 15 | Early Phase 1 | United States |
| 2 | NCT03181399 | April 18, 2018 | 26 August 2019 | Diet Treatment Glucose Transporter Type 1 Deficiency (G1D) | Dietary Treatment of Glucose Transporter Type 1 Deficiency (G1D) | GLUT1DS1;Epilepsy;Glut1 Deficiency Syndrome 1, Autosomal Recessive;Glucose Metabolism Disorders;Glucose Transport Defect;Glucose Transporter Type 1 Deficiency Syndrome;Glucose Transporter Protein Type 1 Deficiency Syndrome | Drug: Triheptanoin | University of Texas Southwestern Medical Center | National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting | 24 Months | 35 Years | All | 45 | Phase 2 | United States |
| 3 | NCT03202108 | August 3, 2017 | 16 December 2017 | Evaluation of Krio in Children and Adults With Epilepsy | A Feasibility Study to Evaluate the Acceptability of Krio, a Food for Special Medical Purposes (FSMP) for Use in the Ketogenic Diet (KD) With Regard to Product Tolerance, Compliance and Acceptability | Ketogenic Dieting;Epilepsy;Glucose Transporter Type 1 Deficiency Syndrome | Dietary Supplement: Krio | Vitaflo International, Ltd | Not recruiting | 3 Years | N/A | All | 15 | N/A | United Kingdom | |
| 4 | NCT02968953 | June 21, 2017 | 25 February 2019 | Treatment With UX007 for a Single Patient With GLUT1 Deficiency Syndrome | Treatment With UX007 (Triheptanoin) for a Single Patient (ERS) With Glucose Transporter 1 (GLUT1) Deficiency Syndrome | Glucose Transporter 1 Deficiency Syndrome | Drug: Triheptanoin | Jerry Vockley, MD, PhD | Ultragenyx Pharmaceutical Inc | Not recruiting | 3 Years | N/A | Female | Phase 2 | United States | |
| 5 | EUCTR2015-000389-69-ES | 22/05/2017 | 28 February 2019 | A trial to assess the long term safety and efficacy of UX007 in subjects who have already participated in a UX007 study. | An Open-label Extension Study to Assess the Long-term Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome | Glucose Transporter Type 1 deficiency syndrome MedDRA version: 19.1 Level: LLT Classification code 10061032 Term: Carbohydrate transport disorder System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Triheptanoin Product Code: UX007 Pharmaceutical Form: Oral solution INN or Proposed INN: no disponible CAS Number: 620-67-7 Current Sponsor code: UX007 Other descriptive name: TRIHEPTANOINA Concentration unit: g/ml gram(s)/millilitre Concentration type: equal Concentration number: 96- | Ultragenyx Pharmaceutical Inc | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | France;United States;Spain;Denmark;Australia;Israel;Italy;United Kingdom | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2015-005536-17-DE | 17/05/2017 | 30 April 2019 | A trial to assess the safety and efficacy of UX007 in patients with movement disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | A Phase 3, randomized, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of UX007 in the treatment of movement disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | Glucose Transporter Type 1 deficiency syndrome MedDRA version: 20.0 Level: LLT Classification code 10061032 Term: Carbohydrate transport disorder System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: UX007 Product Code: UX007 Pharmaceutical Form: Oral solution INN or Proposed INN: Not available CAS Number: 620-67-7 Current Sponsor code: UX007 Other descriptive name: TRIHEPTANOIN Concentration unit: g/ml gram(s)/millilitre Concentration type: equal Concentration number: 0.96- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use | Ultragenyx Pharmaceutical Inc | Not Recruiting | Female: yes Male: yes | 40 | Phase 3 | France;United States;Spain;Australia;Israel;Germany;Italy;United Kingdom | |||
| 7 | NCT02960217 | April 19, 2017 | 4 November 2019 | Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | A Phase 3, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | Drug: Placebo;Drug: UX007 | Ultragenyx Pharmaceutical Inc | Not recruiting | 6 Years | N/A | All | 44 | Phase 3 | United States;France;Germany;Italy;Spain;United Kingdom;Israel | |
| 8 | NCT03041363 | March 29, 2017 | 26 August 2019 | Treatment Development of Triheptanoin (G1D) | Treatment Development of Triheptanoin (C7) for Glucose Transporter Type I Deficiency (G1D): A Phase I Maximum Tolerable Dose Trial | Epilepsy;GLUT1DS1;Glut1 Deficiency Syndrome 1, Autosomal Recessive;Glucose Metabolism Disorders;Glucose Transport Defect;Glucose Transporter Type 1 Deficiency Syndrome;Glucose Transporter Protein Type 1 Deficiency Syndrome | Drug: Triheptanoin | University of Texas Southwestern Medical Center | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 2 Years | 35 Years | All | 36 | Phase 1 | United States |
| 9 | EUCTR2015-005536-17-ES | 17/03/2017 | 3 April 2017 | A trial to assess the safety and efficacy of UX007 in patients with movement disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | A Phase 3, randomized, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of UX007 in the treatment of movement disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | Glucose Transporter Type 1 deficiency syndrome MedDRA version: 19.1 Level: LLT Classification code 10061032 Term: Carbohydrate transport disorder System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: UX007 Product Code: UX007 Pharmaceutical Form: Oral solution INN or Proposed INN: Not available CAS Number: 620-67-7 Current Sponsor code: UX007 Other descriptive name: TRIHEPTANOIN Concentration unit: g/ml gram(s)/millilitre Concentration type: equal Concentration number: 0.96- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use | Ultragenyx Pharmaceutical Inc | Authorised | Female: yes Male: yes | 40 | Phase 3 | United Kingdom;Italy;Germany;Netherlands;Israel;Australia;Ireland;Spain;United States;France | |||
| 10 | NCT02915211 | April 2016 | 3 October 2016 | Evaluation of Keyo in Children With Epilepsy | A Feasibility Study to Evaluate the Acceptability of Keyo, a Food for Special Medical Purposes (FSMP) for Use in the Ketogenic Diet (KD) With Regard to Product Tolerance, Compliance and Acceptability | Intractable Epilepsy;Glucose Transporter Type 1 Deficiency Syndrome;Ketogenic Dieting | Dietary Supplement: Keyo | Vitaflo International, Ltd | Not recruiting | 3 Years | N/A | Both | 17 | N/A | United Kingdom | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT02021526 | December 2015 | 25 February 2019 | Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D) | Treatment Development of Triheptanoin for Glucose Transporter Type I Deficiency | Glucose Transporter Type 1 Deficiency Syndrome;Glut1 Deficiency Syndrome | Drug: Triheptanoin | Juan Pascual | Not recruiting | 30 Months | 55 Years | All | 0 | Phase 1/Phase 2 | United States | |
| 12 | NCT02599961 | September 2015 | 4 November 2019 | Study to Assess the Long Term Safety and Efficacy of UX007 in Subjects With Glucose Type 1 DS | An Open-label Extension Study to Assess the Long-term Safety and Efficacy of UX007 in Subjects With Glucose Transporter Type 1 Deficiency Syndrome | Glucose Transporter Type 1 Deficiency Syndrome | Drug: UX007 | Ultragenyx Pharmaceutical Inc | Not recruiting | 1 Year | N/A | All | 15 | Phase 2 | United States;Australia;Denmark;Spain;United Kingdom | |
| 13 | NCT01993186 | April 2014 | 3 September 2018 | Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study to Assess the Safety and Efficacy of UX007 in Subjects With Glucose Transporter Type 1 Deficiency Syndrome | Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | Drug: UX007 (triheptanoin);Drug: Placebo Oil | Ultragenyx Pharmaceutical Inc | Not recruiting | 1 Year | 100 Years | All | 36 | Phase 2 | United States;Australia;France;Israel;Italy;Spain;United Kingdom;Hungary | |
| 14 | NCT02000960 | April 2014 | 13 June 2016 | Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome | A Controlled N-of-1 Before-and-after Study to Determine Safety and Efficacy Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome | Glucose Transporter Type 1 Deficiency Syndrome | Drug: Triheptanoin | University of British Columbia | Ultragenyx Pharmaceutical Inc | Not recruiting | 1 Year | 18 Years | Both | 3 | Phase 2 | Canada |
| 15 | NCT02018302 | January 2014 | 29 April 2019 | Post Study Continuation of C7 for G1D | Post Study Continuation of C7 for G1D | Glut1 Deficiency Syndrome;Glucose Transporter Type 1 Deficiency Syndrome | Drug: Triheptanoin | Juan Pascual | Not recruiting | 1 Month | 28 Years | All | Phase 2 | United States | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT02036853 | January 2014 | 5 February 2018 | An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome | An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome (GLUT1 DS) | Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS) | Drug: Triheptanoin | Adrian Lacy | Ultragenyx Pharmaceutical Inc | Recruiting | 1 Year | 50 Years | All | 50 | Phase 2 | United States |
| 17 | NCT02014883 | December 2013 | 11 May 2015 | Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS | Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS | Glut1 Deficiency Syndrome | Drug: GLUT1 DS | Institut National de la Santé Et de la Recherche Médicale, France | Ultragenyx Pharmaceutical Inc | Recruiting | 3 Years | N/A | Both | 20 | Phase 2 | France |
| 18 | NCT02018315 | January 2012 | 19 February 2015 | Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D) | Clinical Trial of Citric Acid Cycle Stimulation in Energy-deficiency States: Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D) (NMTUT 2010B) | Glucose Transporter Type 1 Deficiency Syndrome;GLUT1 Deficiency Syndrome | Drug: Triheptanoin | Juan Pascual | Not recruiting | 1 Month | 20 Years | Both | 14 | Phase 1 | United States |